NCT00253630View on ClinicalTrials.gov

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Vorinostat

Given PO

Trial Locations (5)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00253630 - Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter